Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

CHRO

Chromocell Therapeutics Corp.

Apr 18 • 04:00PM ET

1.23

Dollar change -0.76
Percentage change -38.44	%

Healthcare • Biotechnology • USA • AMEX

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.27	Insider Own	70.67%	Shs Outstand	5.88M	Perf Week	-33.08%
Market Cap	7.07M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.69M	Perf Month	-59.70%
Income	-7.38M	PEG	-	EPS next Q	-	Inst Own	8.28%	Short Float	0.16%	Perf Quarter	-
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.08	Perf Half Y	-
Book/sh	-1.10	P/B	-	EPS next Y	-	ROA	-9745.87%	Short Interest	0.00M	Perf Year	-
Cash/sh	0.02	P/C	70.68	EPS next 5Y	-	ROE	-	52W Range	1.61 - 6.00	Perf YTD	-74.48%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-79.58%	Beta	-
Dividend TTM	-	Quick Ratio	0.01	Sales past 5Y	-33.33%	Gross Margin	-	52W Low	-23.92%	ATR (14)	0.33
Dividend Ex-Date	-	Current Ratio	0.01	EPS Y/Y TTM	-276.40%	Oper. Margin	0.00%	RSI (14)	21.27	Volatility	23.33% 13.78%
Employees	8	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-436.04%	Payout	-	Rel Volume	0.78	Prev Close	1.99
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	33.54K	Price	1.23
SMA20	-46.56%	SMA50	-60.12%	SMA200	-60.12%	Trades		Volume	26,533	Change	-38.44%

Apr-09-24 08:30AM	Chromocell Issues Letter to Stockholders from Chief Executive Officer (GlobeNewswire) -8.37%
Mar-21-24 08:30AM	Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler (GlobeNewswire)
Mar-18-24 10:00AM	Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023 (GlobeNewswire) -5.44%
Mar-12-24 10:30AM	Sidoti Events, LLC's Virtual March Small-Cap Conference (ACCESSWIRE)
Mar-11-24 09:00AM	Chromocell to Present at Sidoti Virtual Investor Conference March 13-14 (GlobeNewswire) -6.31%
08:00AM	Loading…
Feb-27-24 08:00AM	Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions (GlobeNewswire)
Feb-21-24 04:47PM	Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million (GlobeNewswire)
Feb-16-24 08:00AM	Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering (GlobeNewswire)

Chromocell Therapeutics Corp. is a clinical-stage biotech company that engages in the development and commercialization of new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. The company was founded on March 19, 2021 and is headquartered in Freehold, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Davis Todd C	Director	Feb 21 '24	Option Exercise	4.80	29,167	140,002	29,167	Feb 23 05:15 PM
Friedberg Ezra M	Director	Feb 21 '24	Option Exercise	4.80	20,641	99,077	520,719	Feb 23 05:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CHRO

Chromocell Therapeutics Corp.

Upgrade your FINVIZ experience